Kirk Campbell, M.D.

NephCure Established Investigator Awardee

Dr. Kirk Campbell is a Professor of Medicine, the Vice Chair for Diversity, Equity and Inclusion, and Director of the Nephrology Fellowship Program at the Icahn School of Medicine at Mount Sinai. In addition to treating patients with kidney disease, Dr. Campbell leads an NIH-funded research program focused on podocyte cell biology, experimental glomerular disease, and clinical trials in the rare kidney disease space. He is a Past- President of the New York Society of Nephrology, a member of NephCure’s Board of Directors, and a standing member of the Pathobiology of Kidney Disease (PBKD) study section at the National Institutes of Health.

New York, New York

Mount Sinai School of Medicine

Lay Summary of the Project:

When podocytes become damaged through diseases such as FSGS, proteinuria develops. With enough podocyte loss, patients can progress to ESRD. Dr. Campbell studies FSGS modeled in the mouse and found that the dendrin gene (DDN) is involved in the regulation of the podocyte. He is examining how DDN mutation can lead to the progression of FSGS, and how it regulates podocyte injury and death. This model may lead to the discovery of new approaches that encourage the repair and/or survival of damaged podocytes.


Sign up to get NephCure’s latest updates.

This field is for validation purposes and should be left unchanged.